Antiviral properties of Hexoral (0.1% solution and 0.2% aerosol for local application) and its constituent hexetidine against viruses causing human respiratory tract infections and herpes virus were studied in vitro. It was found that non-cytotoxic concentrations of hexetidine (alone and as a component of Hexoral) attenuated infectious properties of highly virulent influenza virus A/H5N1, pandemic influenza virus A/H1N1pdm, respiratory syncytial virus, and herpes simplex virus type 1 after a short-term exposure (30 sec) by 100 or more times. It was found that hexidine mostly contributes to the virucidal effect of Hexoral.
Article PDF
Similar content being viewed by others
References
P. G. Deryabin, G. A. Galegov, A. G. Botikov, et al., Vopr. Virusol., 56, No. 1, 21-24 (2011).
D. K. L’vov, I. T. Fedyakina, M. Yu. Shchelkanov, et al., Vopr. Virusol., 51, No. 2, 20-22 (2006).
D. K. L’vov, M. Yu. Shchelkanov, P. G. Deryabin, et al., Vopr. Virusol., 51, No. 1, 11-14 (2006).
A. N. Mironov and N. D. Bunatyan, Manual for Preclinical Testing of Drugs [in Russian], Moscow (2012).
I. T. Fedyakina, M. Yu. Shchelkanov, P. G. Deryabin, et al., Antibiot. Khimioter., 56, No. 3-4, 3-9 (2011).
E. De Clercq, J. Descamps, G. Verheist, et al., J. Commun. Dis., 141, No. 5, 563-573 (1980).
R. Dolin, R. C. Reichman, H. P. Madore, et al., N. Engl. J. Med. 307, No. 10, 580-584 (1982).
I. I. Fedorov, E. M. Kazmina, G. V. Gurskaya, et al., J. Med. Chem, 40, No. 4, 486-494 (1997).
F. G. Hayden, R. L. Atmar, M. Schilling, et al., N. Engl. J. Med. 341, No. 18, 1336-1343 (1999).
R. T. Sarisky, T. T. Nguyen, K. E. Duffy, et al., Antimicrob. Agents Chemother., 44, No. 6 1524-1529 (2000).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 160, No. 9, pp. 339-342, September, 2015
Rights and permissions
About this article
Cite this article
Deryabin, P.G., Galegov, G.A., Andronova, V.A. et al. Analysis of Antiviral Properties of Hexoral In Vitro against Some Viruses that Cause Acute Respiratory Infections and Herpes. Bull Exp Biol Med 160, 353–356 (2016). https://doi.org/10.1007/s10517-016-3169-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-016-3169-9